Pharmaceutical manufacturers are scaling sterile fill-finish infrastructure to clear persistent market shortages for GLP-1 receptor agonist treatments. Capital expenditure in dedicated peptide manufacturing capacity rose 28% this fiscal year.
Contract Manufacturing Agreements
Major drugmakers are securing multi-year capacity reservations with third-party CDMOs, spending billions to convert existing facilities into specialized production lines.
Insurance Coverage Dynamics
Health maintenance organizations are revising coverage criteria, balancing high upfront drug costs against projected long-term reductions in chronic cardiovascular care expenditures.